SCM
BPMC

SCS Capital Management’s Blueprint Medicines BPMC Stock Holding History

SCS Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,163
Closed -$1.94M – 522
2025
Q2 		$1.94M Hold
15,163
– – 0.02% 224
2025
Q1 		$1.34M Buy
+15,163
New +$1.48M 0.02% 235

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

SCS Capital Management's BPMC Position: Q3 2025 in Review

SCS Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 15,163 shares — an estimated $1.94M sold.

SCS Capital Management first reported a position in BPMC in Q1 2025 and held it in 2 quarters. The position peaked at $1.94M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • SCS Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • SCS Capital Management sold 15,163 Blueprint Medicines shares in Q3 2025, an estimated $1.94M.
  • SCS Capital Management first reported a position in Blueprint Medicines in Q1 2025 and held it in 2 quarters.
  • SCS Capital Management's Blueprint Medicines position peaked at $1.94M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on SCS Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.